Sell-rated reports

287 tickers rated Sell
NewestHighest Score Ranks all reports in this rating group by score, highest first.
Builders FirstSource, Inc.
BLDR·Industrials
D ★Strong Sell
Current$64.91
Nov 1, 2026

Builders FirstSource benefits from national scale and long-term demand for efficient residential construction, but weakening margins, elevated leverage, and demanding cash-flow valuation outweigh its cyclical recovery potential.

Score
52
Veradermics, Incorporated
MANE·Healthcare
D ★Strong Sell
Current$102.82
Aug 24, 2026

Veradermics targets a massive, emotionally driven $2 billion aesthetic market with a clever reformulation of a validated hair-loss molecule, but aggressive insider dumping and the binary FDA safety risk surrounding systemic minoxidil make the current multi-billion dollar valuation entirely precarious.

Score
52
Arrowhead Pharmaceuticals, Inc.
ARWR·Healthcare
D ★Strong Sell
Current$47.78
Nov 15, 2026

Arrowhead's differentiated RNAi platform and REDEMPLO expansion could create substantial long-term pharmaceutical revenue, but persistent cash burn, milestone-dependent sales, and uncertain commercial adoption threaten shareholder returns.

Score
51
Telephone and Data Systems, Inc.
TDS·Communication Services
D ★Strong Sell
Current$32.87
Nov 9, 2026

TDS owns valuable broadband, tower, and spectrum assets that support restructuring upside, but persistently negative free cash flow and weak recurring returns threaten shareholder-value creation.

Score
51
Red Rock Resorts, Inc.
RRR·Consumer Discretionary
D ★Strong Sell
Current$47.96
Nov 6, 2026

Red Rock Resorts benefits from a defensible Las Vegas locals casino franchise and new development opportunities, but expensive valuation, elevated leverage, and weak free cash flow limit its near-term investment appeal.

Score
51
The Mosaic Company
MOS·Materials
D ★Strong Sell
Current$22.33
Nov 6, 2026

Mosaic's globally significant phosphate and potash assets offer cyclical recovery potential, but persistent phosphate losses, negative free cash flow, and elevated leverage make the near-term investment case unattractive.

Score
51
Strategy Inc.
MSTR·Technology
D ★Strong Sell
Current$130.51
Nov 1, 2026

Strategy offers leveraged exposure to bitcoin through an established capital markets platform, but substantial dilution, preferred financing obligations, and weak recurring cash generation threaten sustainable per-share value creation.

Score
51
Intel Corporation
INTC·Technology
D ★Strong Sell
Current$65.76
Nov 1, 2026

Intel's server CPU recovery and advanced manufacturing strategy offer meaningful turnaround potential, but heavy capital requirements, shareholder dilution and demanding valuation undermine its near-term investment appeal.

Score
51
Sasol Limited
SSL·Materials
D ★Strong Sell
Current$18.03
Oct 26, 2026

Sasol's improving industrial efficiency and debt reduction support an earnings recovery, but its elevated historical valuation, commodity dependence and demanding cash-flow expectations weaken the investment case.

Score
51
Belite Bio, Inc
BLTE·Healthcare
D ★Strong Sell
Current$164.36
Nov 15, 2026

Belite Bio's successful pivotal Stargardt trial and approaching FDA decision could unlock a valuable retinal-disease franchise, but its multibillion-dollar precommercial valuation and unproven launch economics create substantial downside risk.

Score
50
Scholar Rock Holding Corporation
SRRK·Healthcare
D ★Strong Sell
Current$43.16
Nov 13, 2026

Scholar Rock's FDA-approved muscle-targeted SMA therapy creates a differentiated commercial growth opportunity, but high cash burn, substantial dilution, and demanding adoption expectations constrain its investment appeal.

Score
50
Edgewise Therapeutics, Inc.
EWTX·Healthcare
D ★Strong Sell
Current$46.43
Nov 10, 2026

Edgewise Therapeutics offers potentially differentiated cardiovascular medicines and strong liquidity after a major asset sale, but unproven commercial economics, substantial dilution and clinical execution risk constrain investment appeal.

Score
50